Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A study to find out more about borderline ovarian tumours
This study looked at borderline ovarian tumours and how to improve management.
It was open for people to join between 2010 and 2017. The team looked at the results in 2022.
More about this trial
In this study doctors gathered clinical information, tissue samples and data from follow up visits over many years.
They hoped to predict likely disease outcome (prognosis) for individual women. They wanted to find out if this information could help them to work out what the best management was for an individual.
So in future doctors can have management plans to better suit individual women. They also wanted to develop ways to prevent the disease progression, or to treat it better.
Summary of results
The team found that some factors had a strong influence on whether these tumours came back.
The average age of the women taking part was 60 years of age. The team looked at:
- the type of borderline ovarian tumour
- the stage of the tumour
- blood tests such as
CA-125 pelvic examination
They also looked at the samples of tissue from when the women had surgery to remove their tumour.
They found that the tumour was more likely to come back if:
- there are areas of abnormal cells outside of the ovaries such as in the tummy (abdominal) area
- the tumour was a serous type
- it was a higher stage of disease – all of those who developed a recurrence had stage 3 disease at the time of their diagnosis
They also found that the levels of CA-125 in the blood started to increase in everyone whose cancer came back.
They say that this study highlights the importance of follow up. In particular the importance of checking the levels of CA-125.
Where this information comes from
We have based this summary on the information from the study team. We have not analysed the data ourselves.
How to join a clinical trial
Professor Mona El-Bahrawy
Experimental Cancer Medicine Centre (ECMC)
Imperial College London